Definium (DFTX) news

Definium Therapeutics shares jump 15% after co's anxiety disorder drug meets late-stage trial goal

Definium Therapeutics Inc. (NASDAQ: DFIN) reported a 15% increase in its stock price following the announcement that its investigational drug for generalized anxiety disorder met its primary endpoint in a late-stage clinical trial [1]. The Phase III trial, which evaluated the drug’s efficacy and…

Definium Therapeutics shares resume trading, jumps 24% on data

Definium Therapeutics, Inc. (DFTX) shares surged 24% on Monday, August 11, 2026, following the release of positive topline results from its Phase 3 Emerge study evaluating DT120 Orally Disintegrating Tablet in the treatment of major depressive disorder (MDD). The study met its primary endpoint and…

Definium Therapeutics shares to resume trading at 07:30 am ET

Definium Therapeutics, Inc. (DFTX) announced that its common shares will begin trading on the Nasdaq under the ticker symbol “DFTX” effective at market open on January 15, 2026, following a previously scheduled update . The company emphasized that no action is required by shareholders in connection…

Definium Therapeutics, Inc. announces closing of $805 million upsized public offering, including full exercise of the underwriters’ option to purchase additional shares

Definium Therapeutics, Inc. (Nasdaq: DFTX) has completed a $805 million upsized public offering, including the full exercise of the underwriters’ option to purchase additional shares. The company issued 20,588,236 common shares at $34.00 per share, with the underwriters exercising their 30-day…

Definium Therapeutics prices offering of 20.6M shares at $34 each